Combining development of hypoxia-targeting therapies with biomarker research and development

Convert Pharmaceuticals conducts research and development activities in the field of tumor hypoxia, aiming to bring novel therapeutic agents through to clinical proof-of-concept, with indication and patient selection guided by appropriate biomarkers. Our lead candidate is a hypoxia-activated, cytotoxic compound, currently in advanced pre-clinical development.

Convert Pharmaceuticals - Hypoxia-Activated Prodrugs